Evidence map›Paper›PMID 41144789›Full record

ArticleCancer immunology research2026

Downregulation of HLA Class I Expression through HLA-A DNA Methylation Is Associated with Reduced CD8+ T-cell Infiltration in Cervical Cancer.

Daisuke Yoshimoto, Hitoshi Iuchi, Ayumi Taguchi, Kenbun Sone, Kana Tamai, Ayako Mori, Shuhei Kitamura, Anh Quynh Duong, Aya Ishizaka, Misako Kusakabe and 13 more

Abstract read
In one paragraph

Article in Cancer immunology research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Daisuke Yoshimoto *Department of Obstetrics and Gynecology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.ORCID 0009-0005-3555-2133
Hitoshi Iuchi *Waseda Research Institute for Science and Engineering, Waseda University, Tokyo, Japan.ORCID 0000-0002-2278-3443
Ayumi TaguchiDepartment of Obstetrics and Gynecology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.ORCID 0000-0002-5491-3871
Kenbun SoneDepartment of Obstetrics and Gynecology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.ORCID 0000-0002-7218-6401
Kana TamaiDepartment of Obstetrics and Gynecology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.ORCID 0009-0007-3863-0701
Ayako MoriDepartment of Obstetrics and Gynecology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.ORCID 0009-0006-2389-0271
Shuhei KitamuraDepartment of Obstetrics and Gynecology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.ORCID 0009-0008-1464-4364
Anh Quynh DuongDepartment of Obstetrics and Gynecology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.ORCID 0009-0002-4143-4465
Aya IshizakaDepartment of Obstetrics and Gynecology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.ORCID 0009-0005-1981-4017
Misako KusakabeDepartment of Obstetrics and Gynecology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.ORCID 0009-0002-8670-617X
Yoko YamamotoDepartment of Obstetrics and Gynecology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.ORCID 0009-0009-4168-8351
Akiko TakaseDepartment of Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.ORCID 0009-0006-1421-8774
Masako IkemuraDepartment of Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.ORCID 0000-0002-7148-778X
Hiroko MatsunagaResearch Organization for Nano and Life Innovation, Waseda University, Tokyo, Japan.ORCID 0000-0002-1725-3333
Takayuki IriyamaDepartment of Obstetrics and Gynecology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.ORCID 0000-0001-7970-6695
Iwao KukimotoPathogen Genomics Center, National Institute of Infectious Diseases, Tokyo, Japan.ORCID 0000-0001-9080-1642
Masahito KawazuDivision of Cellular Signaling, National Cancer Center Research Institute, Tokyo, Japan.ORCID 0000-0003-4146-3629
Michiaki HamadaWaseda Research Institute for Science and Engineering, Waseda University, Tokyo, Japan.ORCID 0000-0001-9466-1034
Tetsuo UshikuDepartment of Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.ORCID 0000-0002-1763-8380
Katsutoshi OdaDivision of Integrative Genomics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.ORCID 0000-0002-2468-9573
Haruko TakeyamaResearch Organization for Nano and Life Innovation, Waseda University, Tokyo, Japan.ORCID 0000-0002-2058-8185
Yasushi HirotaDepartment of Obstetrics and Gynecology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.ORCID 0000-0003-0241-9780
Yutaka OsugaDepartment of Obstetrics and Gynecology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.ORCID 0000-0002-6660-1066

Funding

Japan Agency for Medical Research and Development (AMED) 25ama121055Japan Agency for Medical Research and Development (AMED) 25wm0325057h0003Japan Society for the Promotion of Science (JSPS) 23K08839Japan Society for the Promotion of Science (JSPS) 24K19741
6 · The paper itself

Abstract

Human leukocyte antigen class I (HLA-I) is central to tumor immune recognition, but its regulatory mechanisms in cervical cancer remain poorly understood. This study aimed to elucidate the impact of HLA-I regulatory mechanisms on CD8+ T-cell infiltration and identify distinct histotype-specific immune escape strategies across cervical cancer subtypes. Using 98 cervical cancer cases, including squamous cell carcinoma (SCC; n = 53), adenocarcinoma (n = 32), gastric-type adenocarcinoma (GAS; n = 5), small cell carcinoma (Small, n = 4), and mixed histologic types (n = 4), we examined the relationship between CD8+ T-cell infiltration patterns (categorized as infiltrated, excluded, or absent) and HLA-I expression, HLA-A DNA methylation, and HLA-I loss of heterozygosity (LOH). CD8+ T-cell infiltration patterns varied significantly by histologic subtype (P < 0.0001). SCC showed the highest frequency of the infiltrated pattern (73.6%), whereas GAS and Small predominantly displayed an absent pattern. Reduced CD8+ T-cell infiltration correlated with poor survival (P < 0.0001). HLA-I expression mirrored these trends being highest in SCC and lowest in Small and GAS. HLA-A DNA methylation emerged as a key driver of HLA-I downregulation, leading to reduced CD8+ infiltration (P < 0.05). In SCC, both HLA-A methylation and HLA-I LOH contributed to immune evasion; cases lacking these alterations exhibited the highest CD8+ T-cell infiltration levels (P < 0.01). This study identifies distinct HLA-I regulatory mechanisms in cervical cancer, highlighting HLA-A methylation-and particularly HLA-I LOH in SCC-as key drivers of immune evasion. These findings provide a foundation for developing predictive biomarkers and suggest that targeting these specific HLA-I regulatory mechanisms could enhance immunotherapy efficacy.

Indexed as

CD8-Positive T-LymphocytesDNA MethylationHLA-A AntigensLymphocytes, Tumor-InfiltratingUterine Cervical NeoplasmsAdultAgedDown-RegulationFemaleGene Expression Regulation, NeoplasticHumansLoss of HeterozygosityMiddle AgedPrognosisTumor EscapeHLA-A Antigens

Identifiers

PMID41144789
PMCPMC12780734

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.